GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmocann Global Ltd (XTAE:PMCN-M) » Definitions » Cash-to-Debt

Pharmocann Global (XTAE:PMCN-M) Cash-to-Debt : 2.96 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Pharmocann Global Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pharmocann Global's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.96.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pharmocann Global could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Pharmocann Global's Cash-to-Debt or its related term are showing as below:

XTAE:PMCN-M' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.38   Med: 4.78   Max: No Debt
Current: 2.96

During the past 12 years, Pharmocann Global's highest Cash to Debt Ratio was No Debt. The lowest was 1.38. And the median was 4.78.

XTAE:PMCN-M's Cash-to-Debt is ranked better than
66.03% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs XTAE:PMCN-M: 2.96

Pharmocann Global Cash-to-Debt Historical Data

The historical data trend for Pharmocann Global's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pharmocann Global Cash-to-Debt Chart

Pharmocann Global Annual Data
Trend Dec09 Dec10 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.56 4.78 3.06 1.38 2.96

Pharmocann Global Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 1.42 1.38 1.52 2.96

Competitive Comparison of Pharmocann Global's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmocann Global's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmocann Global's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmocann Global's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pharmocann Global's Cash-to-Debt falls into.



Pharmocann Global Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pharmocann Global's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Pharmocann Global's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmocann Global  (XTAE:PMCN-M) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Pharmocann Global Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pharmocann Global's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmocann Global (XTAE:PMCN-M) Business Description

Traded in Other Exchanges
N/A
Address
Ramat Yishai, PO Box 305, Kiryat Tivon, ISR, 3601201
Pharmocann Global Ltd is an Israel-based company engaged in producing medical-related cannabis products which include oil, ointments, tablets, inhalers, rectal and vaginal suppositories, and pre-rolled cigarettes of various types of THC/CBD strains.

Pharmocann Global (XTAE:PMCN-M) Headlines

No Headlines